These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16769887)

  • 1. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice.
    Le Corre S; Klafki HW; Plesnila N; Hübinger G; Obermeier A; Sahagún H; Monse B; Seneci P; Lewis J; Eriksen J; Zehr C; Yue M; McGowan E; Dickson DW; Hutton M; Roder HM
    Proc Natl Acad Sci U S A; 2006 Jun; 103(25):9673-8. PubMed ID: 16769887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.
    Zhang Q; Zhang X; Sun A
    Acta Neuropathol; 2009 Jun; 117(6):687-97. PubMed ID: 19190923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.
    Schindowski K; Bretteville A; Leroy K; Bégard S; Brion JP; Hamdane M; Buée L
    Am J Pathol; 2006 Aug; 169(2):599-616. PubMed ID: 16877359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
    Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
    Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice.
    Uno Y; Iwashita H; Tsukamoto T; Uchiyama N; Kawamoto T; Kori M; Nakanishi A
    Brain Res; 2009 Nov; 1296():148-63. PubMed ID: 19698704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent phosphorylation pattern of tau in P301L tau transgenic mice.
    Deters N; Ittner LM; Götz J
    Eur J Neurosci; 2008 Jul; 28(1):137-47. PubMed ID: 18662339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
    Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M
    Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Puromycin-sensitive aminopeptidase (PSA/NPEPPS) impedes development of neuropathology in hPSA/TAU(P301L) double-transgenic mice.
    Kudo LC; Parfenova L; Ren G; Vi N; Hui M; Ma Z; Lau K; Gray M; Bardag-Gorce F; Wiedau-Pazos M; Hui KS; Karsten SL
    Hum Mol Genet; 2011 May; 20(9):1820-33. PubMed ID: 21320871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy.
    Köhler C; Bista P; Götz J; Schröder H
    Brain Res; 2010 Aug; 1347():111-24. PubMed ID: 20513372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo.
    Nikkel AL; Martino B; Markosyan S; Brederson JD; Medeiros R; Moeller A; Bitner RS
    Neuropharmacology; 2012 Sep; 63(4):606-12. PubMed ID: 22613839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
    Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I
    Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy.
    Wang X; Smith K; Pearson M; Hughes A; Cosden ML; Marcus J; Hess JF; Savage MJ; Rosahl T; Smith SM; Schachter JB; Uslaner JM
    PLoS One; 2018; 13(4):e0195486. PubMed ID: 29624602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
    Sydow A; Mandelkow EM
    Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
    Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
    Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A local insult of okadaic acid in wild-type mice induces tau phosphorylation and protein aggregation in anatomically distinct brain regions.
    Baker S; Götz J
    Acta Neuropathol Commun; 2016 Mar; 4():32. PubMed ID: 27037086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice.
    Terwel D; Lasrado R; Snauwaert J; Vandeweert E; Van Haesendonck C; Borghgraef P; Van Leuven F
    J Biol Chem; 2005 Feb; 280(5):3963-73. PubMed ID: 15509565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substrate-specific reduction of PP2A activity exaggerates tau pathology.
    Deters N; Ittner LM; Götz J
    Biochem Biophys Res Commun; 2009 Feb; 379(2):400-5. PubMed ID: 19126401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.